242 related articles for article (PubMed ID: 28812304)
1. Management of Castration-Resistant, Taxane-Resistant Prostate Cancer.
Beer TM
Oncology (Williston Park); 2017 Aug; 31(8):633-6. PubMed ID: 28812304
[TBL] [Abstract][Full Text] [Related]
2. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
3. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
[TBL] [Abstract][Full Text] [Related]
4. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
Petrylak DP
Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
[TBL] [Abstract][Full Text] [Related]
5. Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity.
Schutz FA; Buzaid AC; Sartor O
Crit Rev Oncol Hematol; 2014 Sep; 91(3):248-56. PubMed ID: 24613528
[TBL] [Abstract][Full Text] [Related]
6. [Metastatic castration-resistant prostate cancer : Use of cabazitaxel taking into consideration current data].
Gschwend JE; Albers P; Bögemann M; Goebell P; Heidenreich A; Klier J; König F; Machtens S; Pantel K; Thomas C
Urologe A; 2018 Jan; 57(1):34-39. PubMed ID: 29071398
[TBL] [Abstract][Full Text] [Related]
7. Impact of taxanes on androgen receptor signaling.
Bai S; Zhang BY; Dong Y
Asian J Androl; 2019; 21(3):249-252. PubMed ID: 29900882
[TBL] [Abstract][Full Text] [Related]
8. Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.
Hotte SJ
Future Oncol; 2017 Feb; 13(4):369-379. PubMed ID: 27712093
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives.
Ruiz de Porras V; Font A; Aytes A
Cancer Lett; 2021 Dec; 523():162-169. PubMed ID: 34517086
[TBL] [Abstract][Full Text] [Related]
10. [Role of chemotherapy in the treatment of castration resistant prostate cancer].
Uemura H
Nihon Rinsho; 2016 Jan; 74(1):143-8. PubMed ID: 26793895
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy in metastatic castration resistant prostate cancer.].
Rosino A; Ballester I; Tudela J; González-Billalabeitia E
Arch Esp Urol; 2018 Sep; 71(8):676-684. PubMed ID: 30319127
[TBL] [Abstract][Full Text] [Related]
12. Molecular alterations and emerging targets in castration resistant prostate cancer.
Lorente D; De Bono JS
Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.
Bracarda S; Sisani M; Marrocolo F; Hamzaj A; Del Buono S; Altavilla A
Expert Rev Anticancer Ther; 2014 Nov; 14(11):1283-94. PubMed ID: 25353258
[TBL] [Abstract][Full Text] [Related]
14. [Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer].
Ecstein-Fraisse E; Su Z
Gan To Kagaku Ryoho; 2014 Jul; 41(7):817-22. PubMed ID: 25131866
[TBL] [Abstract][Full Text] [Related]
15. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
[TBL] [Abstract][Full Text] [Related]
16. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
[TBL] [Abstract][Full Text] [Related]
17. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
[TBL] [Abstract][Full Text] [Related]
18. Novel agents for castration-resistant prostate cancer: Early experience and beyond.
Fujimoto N
Int J Urol; 2016 Feb; 23(2):114-21. PubMed ID: 26311471
[TBL] [Abstract][Full Text] [Related]
19. New treatment options in castration-resistant prostate cancer.
Armstrong AJ
J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):690-3. PubMed ID: 25995432
[TBL] [Abstract][Full Text] [Related]
20. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
Dreicer R
Clin Adv Hematol Oncol; 2015 May; 13(5):293-5. PubMed ID: 26352772
[No Abstract] [Full Text] [Related]
[Next] [New Search]
